1. Home
  2. BIOX vs TVRD Comparison

BIOX vs TVRD Comparison

Compare BIOX & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bioceres Crop Solutions Corp.

BIOX

Bioceres Crop Solutions Corp.

HOLD

Current Price

$0.37

Market Cap

25.2M

Sector

Industrials

ML Signal

HOLD

TVRD

Tvardi Therapeutics Inc.

HOLD

Current Price

$2.49

Market Cap

25.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BIOX
TVRD
Founded
2001
2017
Country
Argentina
United States
Employees
N/A
12
Industry
Agricultural Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
25.2M
25.0M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
BIOX
TVRD
Price
$0.37
$2.49
Analyst Decision
Buy
Buy
Analyst Count
3
7
Target Price
$4.33
$29.50
AVG Volume (30 Days)
280.5K
55.3K
Earning Date
05-19-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$37.82
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.35
$2.48
52 Week High
$5.00
$43.65

Technical Indicators

Market Signals
Indicator
BIOX
TVRD
Relative Strength Index (RSI) 35.69 30.35
Support Level $0.35 N/A
Resistance Level $0.55 $4.42
Average True Range (ATR) 0.03 0.21
MACD -0.00 -0.02
Stochastic Oscillator 1.07 5.12

Price Performance

Historical Comparison
BIOX
TVRD

About BIOX Bioceres Crop Solutions Corp.

Bioceres Crop Solutions Corp is a fully integrated provider of crop productivity solutions, including seeds, seed traits, seed treatments, biologicals, high-value adjuvants, and fertilizers. The company has developed a multi-discipline and multi-product platform capable of providing solutions throughout the entire crop cycle, from pre-planting to transportation and storage. Some of the products offered by the company include fertilizers, inoculants, adjuvants, crop protection solutions, and seeds among others. Its operating segments are crop protection, which derives key revenue, seed and integrated products, and crop nutrition. Geographically, the majority of the company's revenue is generated from Argentina and the rest from Brazil, North America, Latin America, and other regions.

About TVRD Tvardi Therapeutics Inc.

Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.

Share on Social Networks: